SCHEMBL3606159

SCHEMBL3606159

COc1ccc(COc2cc(Oc3c(C=O)c(C(=O)N(C)OC)nn3C)c(Cl)cc2Cl)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.39
CYP1A2 P05177 3/20 0.39
CYP2C9 P11712 3/20 0.39
CYP2C19 P33261 3/20 0.39
ALDH1A1 P00352 2/20 0.39
HDAC8 Q9BY41 2/20 0.37
LMNA P02545 2/20 0.36
POLB P06746 2/20 0.36
CYP3A4 P08684 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
MRGPRX4 Q96LA9 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
SCN9A Q15858 1/20 0.34
NPC1 O15118 3/20 0.33
RAB9A P51151 3/20 0.33
TDP1 Q9NUW8 1/20 0.33
CYP19A1 P11511 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3610531 0.92 KDM4E (0.38) KDM4ECYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL3611047 0.89 CYP1A2 (0.43) KDM4ECYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL3602437 0.85 MAOB (0.40) KDM4ECYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL3612420 0.83 SMN1; SMN2 (0.53) KDM4ECYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL3597562 0.81 SMN1; SMN2 (0.39) KDM4ECYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL3604969 0.81 ALDH1A1 (0.39) KDM4ECYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL3603078 0.81 SMN1; SMN2 (0.38) KDM4ECYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL3605828 0.80 ALDH1A1 (0.38) KDM4ECYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL3605696 0.80 ALDH1A1 (0.44) KDM4ECYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL3614214 0.80 MAPT (0.40) KDM4ECYP1A2CYP2C9CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016396-A1 PYRAZOLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-21 US disclosed
EP-2128138-A1 PYRAZOLE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016396-A1 PYRAZOLE COMPOUND SLC5A1, SLC5A2, GLP1R KDM4E 2049/4885CYP1A2 137/4885CYP2C9 145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.